Other · developed by Rhythm Pharmaceuticals
RM-718 is an investigational agent studied in multiple ascending doses in hypothalamic obesity and Prader-Willi syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06239116 | Phase 1/2 | Hypothalamic Obesity | Active not recruiting | RYTM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hypothalamic ObesityPrader-Willi SyndromePWS
Updated Nov 1, 2026. Something wrong or missing? Report it on the RYTM page.
See RYTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RYTM catalysts and pipeline →